Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis–a retrospective study from a tertiary center

Xinyu Nan, Qian Qin, Cesar Gentille, Joe Ensor, Christopher Leveque, Ravi Pingali, Alexandria T. Phan, Lawrence Rice, Swaminathan Iyer

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Hyperleukocytosis in patients with acute myeloid leukemia (AML) can lead to leukostasis, which if left untreated, has a high mortality. While prompt cytoreductive chemotherapy is essential, treatment with leukapheresis is controversial. This study investigated the outcomes of patients with hyperleukocytosis who received leukapheresis. From 5596 encounters of patients with leukemia seen at Houston Methodist Hospital, we identified 26 patients who had newly diagnosed AML, WBC >50,000/μL, and received leukapheresis. We matched 26 patients who had similar baseline characteristics but did not receive leukapheresis. The primary endpoint was to compare the 28-day mortality rates between the treatment and the control groups. Secondary endpoints were 6-month, 1-year, and 2-year mortality rates. Using multivariate logistic regression analysis, leukapheresis was associated with significantly lower 28-day mortality rate (30.8% vs. 57.7%, p =.022). There was, however, no difference in long-term mortality rate. Our study demonstrates the short-term mortality benefit of using leukapheresis in AML patients presenting with hyperleukocytosis.

Original languageEnglish (US)
Pages (from-to)2110-2117
Number of pages8
JournalLeukemia and Lymphoma
Volume58
Issue number9
DOIs
StatePublished - Sep 2 2017

Keywords

  • Leukapheresis
  • hyperleukocytosis
  • leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis–a retrospective study from a tertiary center'. Together they form a unique fingerprint.

Cite this